Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
At around the same time, Adorno and Horkheimer began planning for a joint work on "dialectical logic," which would later become Dialectic of Enlightenment. Alarmed by reports from Europe, where Adorno's parents suffered increasing discrimination and Benjamin was interned in Colombes, they entertained few delusions about their work's practical effects. "In view of what is now threatening to engulf Europe," Horkheimer wrote, "our present work is essentially destined to pass things down through the night that is approaching: a kind of message in a bottle." As Adorno continued his work in New York with radio talks on music and a lecture on Kierkegaard's doctrine of love, Benjamin fled Paris and attempted to make an illegal border crossing. After learning that his Spanish visa was invalid and fearing deportation back to France, Benjamin took an overdose of morphine tablets. In light of recent events, the Institute set about formulating a theory of antisemitism and fascism. On one side were those who supported Franz Leopold Neumann's thesis, according to which National Socialism was a form of "monopoly capitalism"; on the other were those who supported Friedrich Pollock's "state capitalist theory." Horkheimer's contributions to this debate, in the form of the essays "The Authoritarian State," "The End of Reason," and "The Jews and Europe," served as a foundation for what he and Adorno planned to do in their book on dialectical logic.
=== MeSH D12.644.641 – peptides, cyclic === MeSH D12.644.641.040 – alamethicin MeSH D12.644.641.050 – amanitins MeSH D12.644.641.075 – bacitracin MeSH D12.644.641.142 – capreomycin sulfate MeSH D12.644.641.235 – cyclosporins MeSH D12.644.641.235.300 – cyclosporine MeSH D12.644.641.243 – cyclotides MeSH D12.644.641.252 – dactinomycin MeSH D12.644.641.270 – daptomycin MeSH D12.644.641.297 – depsipeptides MeSH D12.644.641.297.500 – valinomycin MeSH D12.644.641.325 – echinomycin MeSH D12.644.641.380 – ferrichrome MeSH D12.644.641.515 – mycobacillin MeSH D12.644.641.548 – nanotubes, peptide MeSH D12.644.641.582 – nisin MeSH D12.644.641.650 – octreotide MeSH D12.644.641.735 – phalloidine MeSH D12.644.641.780 – polymyxins MeSH D12.644.641.780.110 – colistin MeSH D12.644.641.780.750 – polymyxin b MeSH D12.644.641.802 – streptogramins MeSH D12.644.641.802.249 – mikamycin MeSH D12.644.641.802.374 – pristinamycin MeSH D12.644.641.802.500 – streptogramin group a MeSH D12.644.641.802.500.500 – streptogramin a MeSH D12.644.641.802.750 – streptogramin group b MeSH D12.644.641.802.750.500 – streptogramin b MeSH D12.644.641.802.812 – vernamycin b MeSH D12.644.641.802.875 – virginiamycin MeSH D12.644.641.802.875.500 – streptogramin a MeSH D12.644.641.825 – thiostrepton MeSH D12.644.641.875 – viomycin MeSH D12.644.641.875.250 – enviomycin
=== Other countries === Legislation has been implemented by Japan, Singapore, and Australia that offers subsidies and other incentives to encourage the development of drugs that treat orphan diseases.
Sources: en.wikipedia.org
=== Dietary === In the United States, many people's diets are excessively high in calories, often due to fast food and sugary beverages. Individuals with obesity may consume more calories before feeling full, experience hunger more quickly, or eat in response to stress or anxiety. Per the USDA's Dietary Guidelines for Americans, 2020-2025, most Americans do not follow a healthy dietary pattern. Few individuals being tested for nutrient levels would be able to meet them without the use of fortification or enrichment. Americans eat an abundance of fast food. 36.6% of adults consume fast food on a given day and 2 out of 3 people consume fast food at least once a week. While the negative effects of fast food, such as lack of nutritional value and high amounts of calories, are widely known, fast food remains popular for its convenience, specifically because it is time-efficient and cheap. Quantity of food consumption plays an important role as well. A study shows a significant increase in food portion sizes of marketplace products since the 1970s that exceed the federal standards for dietary guidance. Reasons for this increase include the expansion of the food industry since the seventies, marketing strategies, and customer demand. Extreme differences in portion sizes between the same menu items of the same franchises have also been observed. In some instances, American food portion sizes are as much as double the size of their British counterparts.
The basic principle of displacement chromatography is: there are only a finite number of binding sites for solutes on the matrix (the stationary phase), and if a site is occupied by one molecule, it is unavailable to others. As in any chromatography, equilibrium is established between molecules of a given kind bound to the matrix and those of the same kind free in solution. Because the number of binding sites is finite, when the concentration of molecules free in solution is large relative to the dissociation constant for the sites, those sites will mostly be filled. This results in a downward-curvature in the plot of bound vs free solute, in the simplest case giving a Langmuir isotherm. A molecule with a high affinity for the matrix (the displacer) will compete more effectively for binding sites, leaving the mobile phase enriched in the lower-affinity solute. Flow of mobile phase through the column preferentially carries off the lower-affinity solute and thus at high concentration the higher-affinity solute will eventually displace all molecules with lesser affinities.
The release of a phosphate anion from bound ADP anion into water solution may be considered as an exergonic reaction because the phosphate anion has low molecular mass. Thus, we arrive at the conclusion that the primary release of the inorganic phosphate H2PO4− leads to transformation of a significant part of the free energy of ATP hydrolysis into the kinetic energy of the solvated phosphate, producing active streaming. This assumption of a local mechano-chemical transduction is in accord with Tirosh's mechanism of muscle contraction, where the muscle force derives from an integrated action of active streaming created by ATP hydrolysis.
Sources: en.wikipedia.org
== Evolution == The insulin-like growth factor 2 receptor function evolved from the cation-independent mannose 6-phosphate receptor and is first seen in Monotremes. The IGF-2 binding site was likely acquired fortuitously with the generation of an exonic splice site enhancer cluster in exon 34, presumably necessitated by several kilobases of repeat element insertions in the preceding intron. A six-fold affinity maturation then followed during therian evolution, coincident with the onset of imprinting and consistent with the theory of parental conflict.
=== EC 1.2.7 With an iron–sulfur protein as acceptor === EC 1.2.7.1: pyruvate synthase EC 1.2.7.2: Now included with EC 1.2.7.1, pyruvate synthase. EC 1.2.7.3: 2-oxoglutarate synthase EC 1.2.7.4: anaerobic carbon monoxide dehydrogenase EC 1.2.7.5: aldehyde ferredoxin oxidoreductase EC 1.2.7.6: glyceraldehyde-3-phosphate dehydrogenase (ferredoxin) EC 1.2.7.7: 3-methyl-2-oxobutanoate dehydrogenase (ferredoxin) EC 1.2.7.8: indolepyruvate ferredoxin oxidoreductase EC 1.2.7.9: deleted, identical to EC 1.2.7.3, 2-oxoglutarate synthase EC 1.2.7.10: oxalate oxidoreductase EC 1.2.7.11: 2-oxoacid oxidoreductase (ferredoxin) EC 1.2.7.12: formylmethanofuran dehydrogenase
Brain Basal ganglia Brain stem Medulla Midbrain Pons Cerebellum Cerebrum Cerebral cortex Hypothalamus Limbic system Amygdala Eyes (2) Pineal gland Pituitary gland Thyroid gland Parathyroid glands (4) Thorax
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.